By Serafina Lalany

 

Congress just passed the One Big Beautiful Bill Act (OBBBA)—a 1,200+ page legislative overhaul that reshapes how capital flows through the innovation economy. It’s a deeply polarizing bill, and for good reason: many see it as a direct threat to key social programs and climate commitments, while others view it as a long-overdue reset of fiscal and tax policy.

Amid that broader debate, I’ve been focused on a narrower question: What does this actually mean for early-stage builders and backers?

While the headlines (understandably) focus on the most politically charged provisions, buried in the text are major changes to capital gains treatment, R&D expensing, and sector-specific incentives that will directly impact how startups are formed, financed, and scaled in the coming years.

I put together a breakdown of those changes to help founders and funders understand what’s coming, how it might affect strategy, and where planning may need to shift

The Status (as of July 3, 2025 at 4:40pm CT)

• Passed the House (218-214)
• Passed the Senate (51-50)
• Expected to be signed into law by July 4th

TL;DR: Key Takeaways

• QSBS overhaul is the sleeper headline—huge downstream effects on equity planning and investor psychology
• Full expensing for R&D and equipment is back—a green light for capital-intensive innovation
• AI funding is flowing, but regulatory chaos remains
• Clean tech subsidies didn’t just fade—they got clipped
• Some of the most founder-friendly tax treatment in a decade—but it comes with a $3–4T price tag

1. QSBS Expansion: Quietly Transformational

Section 70431 expands Qualified Small Business Stock (QSBS) treatment. If you’re a founder or early investor, this one matters:

• Increases the cap from $10M to $15M in tax-free gains (indexed going forward)
• Creates a partial exclusion structure (up to 75%) for holders under 5 years
• Clarifies eligibility for a broader set of business models and legal structures

Why this matters: Capital is more patient when the upside is tax-advantaged. This subtly but powerfully shifts incentives back toward early-stage investing, especially in riskier verticals.

Founder POV: Finalizing equity grants, converting SAFEs, or issuing options this year? You’re likely locking in more upside—especially if you can hold for the long run.

2. Full Expensing Returns: R&D + CapEx Leverage

Two changes that seem technical but are game-changing for builders:

• Section 70302 restores immediate expensing for domestic R&D (ending the 5-year amortization window from 2022)
• Section 70301 makes 100% bonus depreciation permanent for qualified equipment

This applies to:

• R&D-heavy tech, biotech, or device startups
• Hardware, energy, and robotics firms burning CapEx early

Why this matters: Cash flow is destiny. When startups can expense real costs in the year they’re incurred, they stretch capital and defer taxes at critical moments. It also improves optics for later-stage investors who care about reported earnings or margins.

Strategic question: Can you front-load product investment this year and capture the write-off while burn is still efficient?

3. AI: Strategic Investment, But No Relief on Compliance

Federal lawmakers dropped the AI preemption provision in the final days of negotiation. So:

• There’s no federal override of state laws—California and others still govern your AI disclosures
• But there’s significant federal money ($150M+) flowing to build science-grade AI infrastructure, particularly through the Department of Energy and national labs

Why this matters: The U.S. government is leaning into dual-use AI for energy, climate modeling, and defense—but not yet touching B2C or B2B oversight. If you’re building in applied science or frontier AI, the grants are coming. If you’re in enterprise SaaS with a generative wrapper, you still need to patchwork compliance.

Translation: No new rules, but real signals on where capital (and legitimacy) might accrue.

4. Clean Tech: Subsidy Window Closes Early

This was the biggest reversal. EV, solar, wind, and hydrogen credits were all trimmed or accelerated:

• EV tax credits end after Q3 2025
• Clean electricity production credits sunset after 2027
• Hydrogen credits expire 5 years earlier than planned

Why this matters: Startups riding demand-side credits to de-risk go-to-market just lost their wedge. This won’t kill clean tech—but it will create an aggressive bifurcation between:

• Companies that can survive without policy support
• Companies whose cost structure depended on it

There is one bright spot: sustainable aviation fuel and domestic nuclear now qualify for expanded MLP (Master Limited Partnership) treatment—unlocking new capital structures.

Strategic choice: Can your sales model stand on its own two feet without federal help by 2027? If not, your fundraising story needs to change—fast.

5. Sector Tailwinds: Defense, Biotech, Advanced Manufacturing

This is where the money is quietly being routed:

• Defense tech: Cybersecurity, low-cost weapons systems, and Indo-Pacific resilience got multi-billion-dollar boosts
• Biotech: Orphan drug pricing protections remain intact; R&D expensing boosts cash-efficiency
• Manufacturing: Section 70307 allows 100% expensing of new U.S.-based factories—no phase-out. Paired with a 35% CHIPS investment credit, the effective cost of CapEx just plummeted

Why this matters: This bill doesn’t just cut or spend—it tilts the ground. If you’re in the right sectors, you’re now competing with a tailwind that wasn’t there a week ago.

6. How to Play It: Founder Operating Manual

If you’re raising:

• Highlight QSBS treatment—especially for new investors coming in this year

If you’re spending:

• Pull CapEx forward into 2025 to capture bonus depreciation
• Capture R&D deductions while you’re still unprofitable

If you’re clean tech:

• Recalculate CAC and ROI with lower post-2026 subsidies
• Surface state and municipal offsets early

If you’re deep tech or defense-adjacent:

• Look into SBIR, DoD, or DOE contracting opportunities while appropriations are fresh

 

Final Thought

This bill is less about big swings and more about tilting the playing field. It rewards conviction, favors long-term holders, and subtly asks founders: can you build something real in a less-subsidized world?

For those who can, the conditions just improved. For those who can’t, the scaffolding is coming down faster than expected.

That’s not good or bad—it’s just the new operating environment. Time to reallocate accordingly.